Please assess the completion status of the following clinical trial:

Trial Title: Quartet Lead and Resynchronization Therapy Options III (QUARTO_III)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient that will be implanted with a Cardiac Resynchronization Therapy (CRT-D) with the MultiPoint Pacing (MPP) feature under the current Guidelines indications for CRT-D implant (including upgrades from single or dual chamber Defibrillator or Pacemaker).~* Patient that will be implanted with a Quartet Left Ventricular (LV) quadripolar lead.~* In sinus rhythm at baseline visit.~* Patients with Left Bundle Branch Block (LBBB)~* Must be willing and able to comply with study requirements.~* Older than 18 years~* Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form.~Exclusion Criteria:~* Already has a CRT device implanted.~* Myocardial Infarction or unstable angina within 40 days prior the enrollment.~* New York Heart Association (NYHA) Class IV~* Recent cardiac revascularization in the 4 weeks prior to enrollment.~* Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) in the 3 months prior the enrollment.~* Classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 12 months.~* Primary valvular disease requiring surgical intervention.~* Atrial Fibrillation (AF):~  * Persistent AF at the time of enrollment or 30 days prior the enrollment~ * Permanent AF not treated with Atrio-Ventricular node ablation within 2 weeks after the CRT-D implant~ * History or incidence of Paroxysmal or Persistent AF within 30 days prior the enrollment~* Patient for whom suitable Transthoracic echocardiographic images for determining the cardiac output (CO) and LV volumes cannot be obtained.~* Undergone a cardiac transplantation or being waiting for it~* Life expectancy \< 6 months~* Pregnancy or planning to become pregnant~* Unable to comply with the follow up schedule~* Currently participating in any other clinical investigation.-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPP ON (Type: EXPERIMENTAL): To activate the Multipoint Pacing (MPP) feature to ON in all patients

Based on this trial design, predict the completion outcome and termination type (if applicable).